Ikonisys SA (ALIKO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ikonisys SA (ALIKO) has a cash flow conversion efficiency ratio of -0.016x as of December 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-257.48K ≈ $-301.02K USD) by net assets (€15.73 Million ≈ $18.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Ikonisys SA (ALIKO) market capitalisation for the company's overall valuation and market capitalisation.
Ikonisys SA - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Ikonisys SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ikonisys SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ikonisys SA ranked by their cash flow conversion efficiency. See ALIKO operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Essen Tech Co. Ltd
KQ:043340
|
-0.038x |
|
Z-Com Inc
TWO:8176
|
-0.008x |
|
Nucletron Electronic Aktiengesellschaft
F:NUC
|
0.004x |
|
Mgenplus Co. Ltd.
KQ:032790
|
-0.049x |
|
BRIDGETEC Corp
KQ:064480
|
-0.028x |
|
Wooree E&L Co. Ltd
KQ:153490
|
-0.111x |
|
Naas Technology Inc ADR
NASDAQ:NAAS
|
-0.015x |
|
Sarawak Consolidated Industries Bhd
KLSE:9237
|
-0.011x |
Annual Cash Flow Conversion Efficiency for Ikonisys SA (2020–2024)
The table below shows the annual cash flow conversion efficiency of Ikonisys SA from 2020 to 2024. View Ikonisys SA stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €14.25 Million ≈ $16.66 Million |
€-1.33 Million ≈ $-1.55 Million |
-0.093x | -60.43% |
| 2023-12-31 | €15.73 Million ≈ $18.39 Million |
€-914.22K ≈ $-1.07 Million |
-0.058x | +9.72% |
| 2022-12-31 | €17.67 Million ≈ $20.66 Million |
€-1.14 Million ≈ $-1.33 Million |
-0.064x | -64.86% |
| 2021-12-31 | €20.01 Million ≈ $23.40 Million |
€-781.42K ≈ $-913.56K |
-0.039x | +85.34% |
| 2020-12-31 | €5.70 Million ≈ $6.66 Million |
€-1.52 Million ≈ $-1.77 Million |
-0.266x | -- |
About Ikonisys SA
Ikonisys S.A., a cell-based diagnostics company, develops, produces, and markets medical diagnostic products for early and accurate detection of cancer diseases in the United States and Europe. It offers Ikoniscope Robotic Microscopes, including Ikoniscope20 that provides automated slide handling, slide scanning, and real-time image capture and analysis; and Ikoniscope20max that automates the flu… Read more